For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895).
External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial / Becherini, Carlotta; Meattini, Icro; Livi, Lorenzo; Garlatti, Pietro; Desideri, Isacco; Scotti, Vieri; Orzalesi, Lorenzo; Sanchez, Luis Jose; Bernini, Marco; Casella, Donato; Nesi, Silvia; Nori, Jacopo; Bianchi, Simonetta; Pallotta, Stefania; Marrazzo, Livia. - In: TUMORI. - ISSN 0300-8916. - 105:3(2019), pp. 205-209. [10.1177/0300891618811278]
External accelerated partial breast irradiation for ductal carcinoma in situ: long-term follow-up from a phase 3 randomized trial
Bernini, Marco;
2019
Abstract
For a long time, accelerated partial breast irradiation (APBI) effectiveness for ductal carcinoma in situ (DCIS) has been debated, due to conflicting published results. Recent encouraging data from phase 3 trials reopened new perspectives for this radiation approach. The aim of the present study was to analyze the long-term efficacy and safety results of the series of patients with DCIS enrolled in the APBI arm of the APBI-IMRT-Florence phase 3 trial (NCT02104895).
| File | Dimensione | Formato | |
|---|---|---|---|
|
2019_Becherini et al_Tumori.pdf
Accesso riservato
Dimensione
78.94 kB
Formato
Adobe PDF
|
78.94 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
